Categories Earnings, Health Care

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG): Q3 2019 Earnings Snapshot

— AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) reported a net loss of $23.62 million or $0.70 per share for the third quarter of 2019, vs. $0.66 per share loss expected

— Revenues dropped to $84.13 million from $122.24 million last year, vs. $88.27 million expected

— Lowered full-year 2019 revenue guidance to $320-$330 million from the earlier outlook of $325-$355 million

— Expects full-year operating loss of $278-$268 million, up from $276 million loss estimated earlier

— Expects adjusted EBITDA loss in the range of $75 million to $65 million for 2019, which is down from the previous forecast of $85-$75 million

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Add Comment
Viewing Highlight